StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3073% below fair value
$0.35−0.01 (-2.51%)

Close on Nov 16, 2026Market cap $37.82MP/E –Yield –

Caribou Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Caribou Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$106.89M. For fiscal 2025 it was -$144.70M. The highest annual figure on record is -$33.55M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$144.70M–
FY2024Dec 31, 2024-$162.69M–
FY2023Dec 31, 2023-$112.53M–
FY2022Dec 31, 2022-$104.78M–
FY2021Dec 31, 2021-$66.00M–
FY2020Dec 31, 2020-$35.22M–
FY2019Dec 31, 2019-$33.55M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.71M–
Q1 FY2026Mar 31, 2026-$25.63M–
Q4 FY2025Dec 31, 2025-$27.77M–
Q3 FY2025Sep 30, 2025-$28.77M–
Q2 FY2025Jun 30, 2025-$46.41M–
Q1 FY2025Mar 31, 2025-$41.75M–
Q4 FY2024Dec 31, 2024-$37.69M–
Q3 FY2024Sep 30, 2024-$37.06M–
Q2 FY2024Jun 30, 2024-$42.65M–
Q1 FY2024Mar 31, 2024-$45.29M–
Q4 FY2023Dec 31, 2023-$36.70M–
Q3 FY2023Sep 30, 2023-$13.05M–
Q2 FY2023Jun 30, 2023-$32.25M–
Q1 FY2023Mar 31, 2023-$30.53M–
Q4 FY2022Dec 31, 2022-$30.07M–
Q3 FY2022Sep 30, 2022-$26.09M–
Q2 FY2022Jun 30, 2022-$28.07M–
Q1 FY2022Mar 31, 2022-$20.55M–
Q4 FY2021Dec 31, 2021-$20.13M–
Q3 FY2021Sep 30, 2021-$18.36M–
Q2 FY2021Jun 30, 2021-$15.73M–
Q1 FY2021Mar 31, 2021-$12.95M–
Q4 FY2020Dec 31, 2020-$14.99M–
Q3 FY2020Sep 30, 2020-$8.00M–

More Caribou Biosciences figures

See a number that looks wrong?